Science Explorer Interactive view Map
Company · Tromsø · Norway

Lytix Biopharma (Norway)

Research works
27
▼ 40% vs 2013–17
Citations
1.1k
42.1 per fractional work
Top-10% rate
12.3%
record average 16.5%
Open access
40%
world 28%

Not ranked overall: Lytix Biopharma (Norway) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at Lytix Biopharma (Norway)?

By fractional works in all years, weighted toward what it does more of than the world: Innate Immunity, Gene Therapy, Immunotherapy, Tumor Targeting, Cancer Immunotherapy, Host Defense, Antimicrobial Peptides and Therapeutic Agents.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 26 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 26 words, with their numbers
  1. Innate Immunity7▲ 74×4 topics
  2. Gene Therapy5▲ 74×3 topics
  3. Immunotherapy5▲ 29×4 topics
  4. Tumor Targeting4▲ 123×2 topics
  5. Cancer Immunotherapy4▲ 98×3 topics
  6. Host Defense4▲ 210×2 topics
  7. Antimicrobial Peptides4▲ 272×1 topic
  8. Therapeutic Agents4▲ 445×1 topic
  9. Tumor Regression3▲ 142×2 topics
  10. Antigen Presentation3▲ 120×2 topics
  11. Immunity3▲ 34×3 topics
  12. Dendritic Cells3▲ 97×1 topic
  13. Tumor Antigen3▲ 137×1 topic
  14. Arginine Deprivation3▲ 227×1 topic
  15. Bacterial Therapy3▲ 227×1 topic
  16. RNA Interference2▲ 67×1 topic
  17. siRNA Delivery2▲ 100×1 topic
  18. Fluorescence Imaging2▲ 56×1 topic
  19. Nanoparticles2▲ 4.8×2 topics
  20. Photodynamic Therapy2▲ 40×2 topics
  21. Photothermal Therapy2▲ 74×1 topic
  22. Drug Discovery2▲ 15×4 topics
  23. Click Chemistry1▲ 50×1 topic
  24. Copper-Catalyzed Cycloaddition1▲ 120×1 topic
  25. Cyclotides1▲ 216×1 topic
  26. Sortase1▲ 216×1 topic

Which research topics does Lytix Biopharma (Norway) publish most on?

By volume in 2022–2025: RNA Interference and Gene Delivery, Antimicrobial Peptides and Activities, Cancer Research and Treatments and CAR-T cell therapy research.

  1. 1 RNA Interference and Gene Delivery Molecular Biology 0 works
  2. 2 Antimicrobial Peptides and Activities Microbiology 0 works
  3. 3 Cancer Research and Treatments Biotechnology 0 works
  4. 4 CAR-T cell therapy research Oncology 0 works
  5. 5 Immunotherapy and Immune Responses Immunology 0 works
  6. 6 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  7. 7 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 0 works
  8. 8 Virus-based gene therapy research Genetics 0 works
  9. 9 Intestinal Malrotation and Obstruction Disorders Surgery 0 works
  10. 10 Gallbladder and Bile Duct Disorders Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available40.0%not open60.0%

World: 28% of research is openly available.

with international co-authors44.9%domestic only55.1%

World: 19% is written across borders.

How has Lytix Biopharma (Norway)'s research output changed?

Output in 2018–2022 was 40% lower than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Tromsø

All research institutions in Tromsø

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.